SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity - 12/05/21
, Giovanni Sotgiu c, Laura Saderi c, Antonio Voza d, Stefano Aliberti a, b, Francesco Amati a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms.
We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-life effectiveness of SARS-CoV-2 vaccination, including logistical issues associated to vaccine availability, delivery, and immunization strategies. On this background, new variants of SARS-CoV-2 are discussed.
We also provided a critical view on vaccination in special populations at higher risk of infection or severe disease as elderly people, pregnant women and immunocompromised patients. A final paragraph addresses safety on the light of the unprecedented reduction of length of the vaccine development process and faster authorization.
Le texte complet de cet article est disponible en PDF.Highlights |
• | A global vaccination strategy based on efficacious vaccines is among the most relevant unmet needs in COVID-19 management. |
• | Vaccine platforms can be conventional and next generation. To date, phase-3 trials are published for 4 vaccines. |
• | The definition of vaccine efficacy is challenging and clinical endpoints are heterogeneous. |
• | Several factors might affect the effectiveness of a mass vaccination and the herd immunity. |
Keywords : SARS-CoV-2, COVID-19, Vaccination, Primary prevention
Plan
Vol 180
Article 106355- avril 2021 Retour au numéro
Article précédent
- COVID-19: Why does disease severity vary among individuals?
- Saeed Samadizadeh, Maha Masoudi, Mostafa Rastegar, Vahid Salimi, Mahsa Bataghva Shahbaz, Alireza Tahamtan
- Mouthpiece ventilation in neuromuscular disorders: Narrative review of technical issues important for clinical success
- Michel Toussaint, Michelle Chatwin, Miguel R. Gonçalves, Jésus Gonzalez-Bermejo, Joshua O. Benditt, Doug McKim, Jesus Sancho, Brit Hov, Valeria Sansone, Hélène Prigent, Annalisa Carlucci, Peter Wijkstra, Barbara Garabelli, Joan Escarrabill, Tiago Pinto, Nicolas Audag, Laura Verweij-van den Oudenrijn, Adam Ogna, Wendy Hughes, Christian Devaux, Johann Chaulet, Tiina Andersen, ENMC Respiratory Therapy Consortium
Bienvenue sur EM-consulte, la référence des professionnels de santé.